Hypoxia‐Responsive Tetrameric Supramolecular Polypeptide Nanoprodrugs for Combination Therapy

Abstract Despite the intense progress of photodynamic and chemotherapy, however, they cannot prevent solid tumor invasion, metastasis, and relapse, along with inferior efficacy and severe side effects. The hypoxia‐responsive nanoprodrugs integrating photodynamic functions are highly sought to address the above‐mentioned problems and overcome the tumor hypoxia‐reduced efficacy. Herein, a hypoxia‐responsive tetrameric supramolecular polypeptide nanoprodrug (SPN‐TAPP‐PCB4) is constructed from the self‐assembly of tetrameric porphyrin‐central poly( l ‐lysine‐azobenzene‐chlorambucil) (TAPP‐(PLL‐Azo‐CB)4) and an anionic water‐soluble [2]biphenyl‐extended‐pillar[6]arene (AWBpP6) via the synergy of hydrophobic, π – π stacking, and host–guest interactions. Upon laser irradiation, the central TAPP can convert oxygen to generate single oxygen ( 1 O 2 ) to kill tumor cells. Furthermore, under the acidic and PDT‐aggravated hypoxia tumor cell microenvironment, SPN‐TAPP‐PCB4 is rapidly disassembled, and then efficiently releases activated CB through the hypoxic‐responsive cleavage of azobenzene linkages. Both in vitro and in vivo biological studies showcase synergistic cancer‐killing actions between photodynamic therapy (PDT) and chemotherapy (CT) with negligible toxicity. Consequently, this supramolecular polypeptide nanoprodrug offers an effective strategy to design a hypoxia‐responsive nanoprodrug for a potential combo PDT‐CT transition.